NEW YORK (GenomeWeb News) - LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said today.
 
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.